The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

Ozempic and similar drugs are popular with consumers for their weight-loss properties, but a new study suggests they could ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Novo Nordisk shares rose Wednesday after fourth ... behind Eli Lilly & Co. Details about its next-generation weight loss drugs CagriSema and amycretin are also in focus. It's been a rocky few ...